Q2 2026 saw minimal revenue and a net loss of $14.5M, with ongoing investment in R&D and commercialization of the proteomics platform. Cash and investments of $129.2M are expected to fund operations for at least 12 months, but additional capital will be needed as losses continue and commercializati…
Q2 2026 saw minimal revenue and a net loss of $14.5M, with ongoing investment in R&D and commercialization of the proteomics platform. Cash and investments of $129.2M are expected to fund operations for at least 12 months, but additional capital will be needed as losses continue and commercialization ramps up.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
